Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05198310 |
|
Recruitment Status :
Active, not recruiting
First Posted : January 20, 2022
Last Update Posted : March 12, 2024
|
Sponsor:
Kiniksa Pharmaceuticals, Ltd.
Information provided by (Responsible Party):
Kiniksa Pharmaceuticals, Ltd.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Actual Primary Completion Date : | February 8, 2024 |
| Estimated Study Completion Date : | May 2024 |